So sánh Chi Phí của Các Phương Pháp Điều Trị Tăng Sinh Prostate Lành Tính

Herr HW. The enlarged prostate: a brief history of its surgical treatment. BJUI. 2006;98(5):947–52. Napalkov P, Maisonneuve P, Boyle P. Worldwide patterns of prevalence and mortality from benign prostatic hyperplasia. Urology. 1995;46:41–6. Xu PJ, Barnes JM, Choe EM, Syed JR, Siddiqui SA. Variability of retail pricing of generic urologic medications in a major US metropolitan area. Urology. 2019;125:29–33. Messina R, Mirone V. Benign prostatic hyperplasia—an economic assessment of fixed combination therapy based on a literature review. Arch Ital di Urol Androl organo Uff [di] Soc Ital di Ecogr Urol e Nefrol. 2015;87:185–9. Gravas S, Oelke M. Current status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH. World J Urol. 2010;28(1):9–15. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. NEJM. 2003;349:2387–98. Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123–31. Kaplan SA, et al. Time course of incident adverse experiences associated with doxazosin, finasteride and combination therapy in men with benign prostatic hyperplasia: the MTOPS trial. J Urol. 2016;195(6):182. Foster HE, Barry MJ, Dahm P, Gahndi MC, Kaplan SA, Kohler TS, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatichyperplasia: AUA Guideline. J Urol. 2018;200(3):612–9. Varda BK, Wang Y, Chung BI, Lee RS, Kurtz MP, Nelson CP, et al. Has the robot caught up? National trends in utilization, preoperative outcomes, and cost for open, laparoscopic, and robotic pediatric pyeloplasty in the United States from 2003 to 2015. J Pediatr Urol. 2018;14(4):336.e1–8. •• Kaplan AL, et al. Measuring the cost of care in benign prostatic hyperplasia using time-driven activity-based costing (TDABC). Healthcare. 2015;3(1):43–8. Use of time-driven activity-based costing to compare costs associated with five different surgical options for BPH treatment. Masucci L, et al. Cost analysis of Greenlight photoselective vaporization of the prostate compared to transurethral resection of the prostate for benign prostatic hyperplasia. Can Urol Assoc J. 2018;12(12):382–7. Brown AD. Minimally invasive treatment for benign prostatic hyperplasia: economic evaluation from a standardized hospital case costing system. Cardiovasc Intervent Radiol. 2019;42(4):520–7. •• Ulchaker JC, Martinson MS. Cost-effectiveness analysis of six therapies for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Clinicoecon Outcomes Res. 2018;10:29–43. Cost-effectiveness analysis of six current BPH treatments from payers’ perspective, using IPSS scores, adverse events, and retreatment rates to estimate ICERs for pairs of treatments. Cockrell R, Lee DI. Robotic-assisted simple prostatectomy: expanding on an established operative approach. Curr Urol Rep. 2017;18:37. Sun F, Sun X, Shi Q, Zhai Y. Transurethral procedures in the treatment of benign prostatic hyperplasia. Medicine (Baltimore). 2018;97(51):e13360. •• Chung ASJ, Wood HH. Update on minimally invasive surgery and benign prostatic hyperplasia. Asian J Urol. 2018;5(1):22–7. Evaluation of novel minimally invasive surgical options through review of literature, with particular focus on studies published in the preceding five years. McVary KT, Rogers T, Roehrborn CG. Rezum water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled trials. Urology. 2019;126:171–9. Roehrborn CG, et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T study. Can J Urol Int. 2017;24(3):8802–13. Rukstalis D, Grier D, Stroup SP, Tutrone R, deSouza E, Freedman S, et al. Prostatic urethral lift (PUL) for obstructive median lobes: 12 months results of the MedLift study. Prostate Cancer Prostatic Dis. 2018. https://doi.org/10.1038/s41391-018-0118-x. •• Davis NF, et al. Medical therapy versus transurethral resection of the prostate (TURP) for the treatment of symptomatic benign prostatic enlargement (BPE): a cost minimisation analysis. World J Urol. 2018;37:873–8. https://doi.org/10.1007/s00345-018-2454-9. Use of a prospective, multicenter registry across Europe to evaluate the relative cost of BPH medical therapy and TURP. Smith C, Craig P, Taleb S, Young S, Golzarian J. Comparison of traditional and emerging surgical therapies for lower urinary tract symptoms in men: a review. Cardiovasc Intervent Radiol. 2017;40:1176–84. Benejam-Gual JM, et al. Cost effectiveness analysis at 2 years of surgical treatment of benign prostatic hyperplasia by photoselective vaporization of the prostate with GreenLight-photo vaporization 120 W versus transurethral resection of the prostate. Actas Urol Esp. 2014;38(4):238–43. •• Gill BC, Ulchaker JC. Costs of managing benign prostatic hyperplasia in the office and operating room. Curr Urol Rep. 2018;19(9):72. Review of the relative costs of BPH therapy including medical therapy, operating room based surgical therapy and office-based procedures from the payers’ perspective. Erman A, Masucci L, Krahn MD, Elterman DS. Pharmacotherapy vs surgery as initial therapy for patients with moderate-to-severe benign prostate hyperplasia: a cost-effective analysis. BJU Int. 2018;122(5):879–88. Egan KB. The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms. Urol Clin North Am. 2016;43(3):289–97. Taub DA, Wei JT. The economics of benign prostatic hyperplasia and lower urinary tract symptoms in the United States. Curr Urol Rep. 2006;7(4):272–81.